Welcome to our dedicated page for Amarin news (Ticker: AMRN), a resource for investors and traders seeking the latest updates and insights on Amarin stock.
Amarin Corporation plc develops and commercializes cardiovascular therapeutics centered on icosapent ethyl, marketed as VASCEPA in the United States and VAZKEPA in Europe. Company news commonly covers product revenue, cash flow, U.S. prescription trends, partner-led international commercialization, and European distribution under an exclusive licensing and supply agreement with Recordati.
Updates also include medical-society guideline discussions, REDUCE-IT analyses, peer-reviewed publications, and scientific meeting presentations on cardiovascular risk reduction, elevated triglycerides, eicosapentaenoic acid, and lipoprotein(a) oxidation.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Amarin Corporation plc (NASDAQ: AMRN) will host a conference call on May 3, 2023, at 8:00 a.m. ET to discuss its first quarter 2023 financial results. This event will take place following the release of the financial results in pre-market hours. Investors can access the call through the company’s website or by dialing in. The company, known for its innovative approach to cardiovascular disease management, has rapidly evolved from a research foundation to commercial expansion, emphasizing the treatment of cardiovascular risks not addressed by traditional therapies.
Amarin Corporation plc (NASDAQ:AMRN) has appointed Aaron Berg as Interim President and CEO and Oliver O’Connor as a new independent Director, effective immediately. Berg, who has over 25 years of biopharmaceutical experience and has been with Amarin since 2012, aims to advance the company's strategy in cardiovascular disease management and optimize operations. His leadership is expected to enhance the value of VASCEPA for patients globally. O’Connor brings extensive experience in government, policy, and biopharma, which the board believes will be crucial for unlocking VASCEPA’s value outside the U.S. The board is working to identify a permanent CEO.
Amarin Corporation (NASDAQ:AMRN) has received regulatory approval from Israel's Ministry of Health for VAZKEPA (icosapent ethyl). This approval allows the use of VAZKEPA to reduce the risk of cardiovascular events in adult statin-treated patients with elevated triglycerides and other high-risk characteristics. Heart disease is a significant health concern in Israel, being the second leading cause of death among individuals aged 45 and older. Amarin is actively pursuing partnerships and will begin preparing for pricing and reimbursement strategies in Israel starting in 2024.
Amarin Corporation (NASDAQ: AMRN) has announced that its new board, appointed two weeks ago, is committed to enhancing shareholder value. They emphasize VASCEPA's potential to improve cardiovascular outcomes and generate cost savings for payors. The board recognizes the challenges ahead but aims to cultivate a successful company culture for employees. They believe VASCEPA can unlock significant shareholder value as they engage actively with shareholders. The company, headquartered in Dublin and Bridgewater, New Jersey, is dedicated to advancing cardiovascular disease management.